Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study
Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real‐world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first‐line therapeutic antibody ustekinumab. The impact of di...
Saved in:
Main Authors: | Shan Pan (Author), Teresa Tsakok (Author), Nick Dand (Author), Dagan O. Lonsdale (Author), Floris C. Loeff (Author), Karien Bloem (Author), Annick deVries (Author), David Baudry (Author), Michael Duckworth (Author), Satveer Mahil (Author), Angela Pushpa‐Rajah (Author), Alice Russell (Author), Ali Alsharqi (Author), Gabrielle Becher (Author), Ruth Murphy (Author), Shyamal Wahie (Author), Andrew Wright (Author), Christopher E.M. Griffiths (Author), Nick J. Reynolds (Author), Jonathan Barker (Author), Richard B. Warren (Author), A. David Burden (Author), Theo Rispens (Author), Joseph F. Standing (Author), Catherine H. Smith (Author), on behalf of the BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Psoriasis and Genetics
by: Nick Dand, et al.
Published: (2020) -
Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
by: Georgia Lada, et al.
Published: (2022) -
The Iraq Study Group Report
by: Iraq Study Group (U.S.) -
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration
by: The MMR-158 Study Group
Published: (2019) -
Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study
by: The MMR-162 Study Group
Published: (2018)